Compare
Adial Pharmaceuticals, Inc. vs Kairos Pharma, Ltd. vs Vyome Holdings, Inc vs Serina Therapeutics, Inc.
| Latest fiscal year | Adial Pharmaceuticals, Inc. ADIL | Kairos Pharma, Ltd. KAPA | Vyome Holdings, Inc HIND | Serina Therapeutics, Inc. SER |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $319.7K | $130.0K |
| Revenue growth (YoY) | n/a | n/a | +24.4% | +132.1% |
| Gross margin | n/a | n/a | 68.4% | n/a |
| Operating margin | n/a | n/a | n/m | n/m |
| Net margin | n/a | n/a | n/m | n/m |
| Net income | -$7.98M | -$5.45M | -$10.26M | -$19.18M |
| EPS (Diluted) | -$11.93 | -$0.30 | -$4.86 | -$1.91 |
| Operating cash flow | -$6.49M | -$3.44M | -$3.75M | -$17.95M |
| Free cash flow | n/a | n/a | n/a | -$18.01M |
| Cash & equivalents | $5.88M | $4.49M | $4.98M | $3.06M |
| Total assets | $6.67M | $6.54M | $6.50M | $6.95M |
| Total liabilities | $1.40M | n/a | $2.74M | $6.99M |
| Shareholders' equity | $5.28M | $6.34M | $3.76M | -$37.0K |
| Return on year-end equity | -151.2% | -85.9% | -272.8% | n/a |
| Shares outstanding | 1.11M | 20.82M | 5.92M | 10.77M |
Revenue, most recent five fiscal years
| Fiscal year | Adial Pharmaceuticals, Inc. | Kairos Pharma, Ltd. | Vyome Holdings, Inc | Serina Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $319.7K Ended 2025-12-31 | $130.0K Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $256.9K Ended 2024-12-31 | $56.0K Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $8.68M Ended 2023-12-31 | $3.15M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $11.24M Ended 2022-12-31 | $34.0K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $13.60M Ended 2021-12-31 | $144.0K Ended 2021-12-31 |